Nasus Pharma Ltd. (NSRX) Stock Price & Analysis
Nasus Pharma Ltd. (NSRX) closed at USD 3.17 on Thursday, October 15, 2026, down 0.47% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.18; the Oct 15, 2026 session ranged USD 3.05–3.18 on volume of 6,514 shares. Market capitalization is $37.07M, with a 52-week range of USD 1.98–9.5 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NSRX.md
Key facts (NSRX)
- Analysts: Strong Buy (mean 1.00 on a 1–5 scale) (2 analysts), mean target USD 19.67 (range 18–22).
- Total return with dividends: 1Y -60.0% vs S&P 500 +18.1%; 5Y -60.9% vs S&P 500 +85.1%.
Analysts (NSRX)
Consensus Strong Buy (mean 1.00 on a 1–5 scale), 2 analysts; mean target USD 19.67 (low 18, high 22).
Total return (dividends reinvested) (NSRX)
| 1Y (from 2025-10-16) | 5Y (from 2025-08-11) | |
|---|---|---|
| Total return | -60.0% | -60.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -60.2% | -54.9% |
| Volatility (annualized) | 104.4% | 95.0% |
| Max drawdown | -78.0% (Dec 2025→Mar 2026) | -73.0% (Aug 2025→Apr 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 3.17 |
|---|---|
| Change | ▼ 0.47% (down) |
| Previous Close | USD 3.18 |
| Open | USD 3.22 |
| Day Range | USD 3.05 – 3.18 |
| 52-Week Range | USD 1.98 – 9.5 |
| Volume | 6,514 shares |
| Market Cap | $37.07M |
| Exchange | ASE |
Technical Analysis (NSRX)
Nexqual's technical model rates NSRX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.65 (neutral) |
| vs SMA50 | Below (USD 3.64) |
| MACD | -0.09 (negative) |
Analyst Ratings (NSRX)
Wall Street analysts rate NSRX "Strong Buy" based on 2 analysts, with a mean price target of USD 19.67 (range USD 18–22), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 19.67 |
| High Target | USD 22 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (NSRX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.54 vs est -0.23 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (NSRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -316.04% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.77 |
| Total Cash | $11.82M |
| Total Debt | $103,000 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (NSRX)
Nexqual rates Nasus Pharma Ltd.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $12M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M (TTM) |
| Efficiency | Critical — ROE -316%, ROA -96.7% |
Ownership (NSRX)
| Insider Ownership | +49.15% |
|---|---|
| Institutional Ownership | +18.36% |
| Shares Outstanding | 11.71M |
| Float | 5.46M |
| Short % of Float | +1.19% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (NSRX)
Nasus Pharma Ltd. is led by Brendan P. O'Grady (age 58), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Brendan P. O'Grady (age 58) |
|---|---|
| Co-Founder & Executive Chairman | Ehud Moshe Gilboa (age 59) |
| Co-Founder, Director, Chief Medical Officer & Chief Development Officer? | Dalia Megiddo M.B.A. (age 73) |
| Director of Finance & Interim CFO | Oren Elmaliach (age 41) |
| Director of CMC & Product Development | Galia Temtsin Kryaz (age 58) |
Major Backers & Investors (NSRX)
Notable institutional backers of Nasus Pharma Ltd. include Balyasny Asset Management LP, Cable Car Capital, LP, Velan Capital Investment Management LP, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Balyasny Asset Management LP | 7.67% |
| Cable Car Capital, LP | 5.26% |
| Velan Capital Investment Management LP | 3.07% |
| Hudson Bay Capital Management Lp | 1.15% |
| Bleichroeder LP | 0.77% |
| Citadel | 0.19% |
| Xtx Topco Ltd | 0.14% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGN | Organon & Co. | USD 13.76 | ▼ 0.07% |
| GRFS | Grifols, S.A. | USD 7.54 | ▲ 5.16% |
| BIIB | Biogen Inc. | USD 235.35 | ▲ 2.82% |
| SNY | Sanofi | USD 40.29 | ▲ 2.99% |
| GSK | GSK plc | USD 49.02 | ▲ 5.94% |
| BMY | Bristol-Myers Squibb Company | USD 60.57 | ▲ 6.88% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt